Thermo King’s Truck Hybrid Refrigeration Units Hit the Roads
Thermo King®, a leader in transport temperature control solutions and a brand of Trane Technologies (NYSE: TT), today announced that its new hybrid refrigeration systems for trucks and high-loaders are being delivered to customers across Europe. The new T-Series Hybrid and UT Hybrid refrigeration systems seamlessly switch between diesel and electric mode allowing transporters to operate in inner cities, residential areas and low emission zones with the unit’s diesel engine turned off.
Greggs, UK’s leading bakery food-on-the-go retailer with over 1,800 shops nationwide and serving over six million customers a week, is one of the first customers in Europe to experience the benefits of the new hybrid refrigeration systems. Three new trucks with Thermo King’s hybrid systems will contribute to lowering the environmental impact and reducing operating costs of their truck transport operations in central London.
“Thermo King units have been our systems of choice for several years now. Their units have delivered good flexibility and work efficiency to our operations, and we could also always count on the Thermo King dealer service network to support us,” said Richard Penna, group logistics manager at Greggs. “We’re very cautious about the sustainability of our transport operations. It is paramount for us to operate in inner cities with as little noise and reduced emissions as possible. It was a natural choice to work with Thermo King and equip our trucks with these new units that can easily switch from diesel operation to electric, reduce the sound level and eliminate emissions. On top of that, we expect to benefit from the lower daily fuel consumption.”
“Thermo King Hybrid technology was designed to help transport and delivery companies future-proof their refrigerated operations and investments. With this solution they can stay ahead of regulations, control their total cost of ownership and achieve important sustainability goals,” said Colm O’Grady, product manager at Thermo King. “Thermo King was the first to offer its European customers a trailer hybrid refrigeration. Now, our truck transport customers can also benefit from this cleaner and electrified transport refrigeration to make urban distribution more flexible and sustainable.”
The new hybrid single- and multi-temperature solution for trucks feature Frigoblock alternator and inverter-drive technology. The nose-mount T-Series Hybrid and under-mount UT Hybrid refrigeration automatically switches between electric and diesel operation as required or necessary. This enables the transport companies to operate in inner cities, residential areas and low emission zones with the refrigeration unit’s diesel engine turned off.
The system is also well accepted by drivers, mainly due to the simple and smooth transition from one drive technology to the other. The driver only needs to set the vehicle when leaving the depot and the system will switch electric and diesel modes seamlessly during the working day depending on the unit’s requirements.
The T-Series Hybrid and UT Hybrid solutions are aligned with Trane Technologies’ 2030 sustainability commitments, and the commitment to reduce customers’ carbon emissions by one gigaton – equivalent to the annual emissions of Italy, France and the United Kingdom combined.
About Thermo King
Thermo King is a brand of Trane Technologies (NYSE: TT), a global climate innovator, and a worldwide leader in sustainable transport temperature control solutions. Thermo King has been providing transport temperature control solutions for a variety of applications, including trailers, truck bodies, buses, air, shipboard containers and railway cars since 1938. For more information, visit www.europe.thermoking.com or www.tranetechnologies.com.
About Trane Technologies
Trane Technologies is a global climate innovator. Through our strategic brands Trane® and Thermo King®, and our portfolio of environmentally responsible products and services, we bring efficient and sustainable climate solutions to buildings, homes and transportation. For more information, please visit tranetechnologies.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200719005017/en/
Contact information
Media:
Geraldine Velner, Trane Technologies
+353-85-704-6944
Geraldine.velner@tranetechnologies.com
Investors:
Zachary Nagle, Trane Technologies
+1-704-990-3913
Zachary.nagle@tranetechnologies.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom